Hematology

1ST Biotherapeutics and twoXAR Form co-development collaboration to discover and develop new brain cancer treatments

Scientists at the University of Cambridge have identified mechanisms by which drug sensitivities characteristic of ATM-deficient cells can be counteracted by changes in other genes; these results are important for understanding cancer drug resistance in the context of sporadic cancers, as well as highlighting potential therapeutic targets for ataxia-telangiectasia

Proprietary cfRNA-enriched, real-time PCR testing rapidly identifies all patients with NTRK fusion-positive cancers potentially eligible for new TRK inhibitor targeted therapy

MorphoSys and I-Mab sign strategic agreement for novel immuno-oncology agent MOR210

Company announces results for ovarian cancer and an approval for breast cancer

Exelixis and Ipsen initiate Phase 3 pivotal trial (COSMIC-312) of cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma

Phase 2 interim data evaluating the combination of pracinostat and azacitidine in patients with Myelodysplastic Syndrome presented at the 2018 American Society of Hematology Annual Meeting

Gamifant (emapalumab) is the first treatment specifically for patients with primary hemophagocytic lymphohistiocytosis

Research team publishes research on the anticancer effects of retinoic acid on cancer stem cells

Moleculin announces new data discovery for presentation at Society for Neuro-Oncology meeting

Pacific Biosciences’ recent advances with its Sequel SMRT technology, combined with Illumina’s infrastructure, will expand biological discovery and clinical insight

Cisplatin combined with radiation therapy established as standard of care for HPV-related head and neck cancer